AstraZeneca Shareholders Approve Proposed Acquisition of Alexion

A requisite majority of AstraZeneca shareholders has approved the proposal to acquire the entire common stock of Alexion Pharmaceuticals, Inc. (Alexion) at a general meeting. The company continues to expect the acquisition will close in Q3 2021, subject to approval by Alexion shareholders, certain regulatory approvals, and other customary closing conditions.

The acquisition was described in a circular to shareholders on 12 April 2021. The resolution was set out in the Company’s notice of general meeting and voted on by way of a poll. The results are set out below.

Pascal Soriot, Chief Executive Officer, said: “The approval of the acquisition by AstraZeneca shareholders represents a significant step toward combining Alexion’s leadership in complement biology and rare diseases with AstraZeneca’s expertise in precision medicine and growing presence in immunology. We look forward to together advancing life-changing science and bringing even more medicines to patients globally.”